184 results found.
                
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As we wrote in the December ...
Anika Therapeutics Distributes HA-based Therapies Again
Anika Therapeutics resumed global distribution of HYALOFAST and HYALOGRAFT-C therapies for cartilage repair, following a
3Q18 and 9 Month 2018 Performance Highlights for Public Companies
By Mike Evers Our recap highlights 3Q18 developments and ORTHOWORLD's projection of 2018 full-year revenue for the first publicly traded orthopaedic companies to report. Exhibits 1 and 2 below show year over year company performance for 3Q18 and nine months ending September 30, 2018...
Anika Therapeutics Reports 3Q18 Revenue of $24.1MM, +0.4% vs. 3Q17
Anika Therapeutics posts 3Q18 orthobiologic revenue of $24.1MM, +0.4% vs. 3Q17.
Revenue Review: 1H18 Growth and 2Q18 Performance Highlights for Public Companies
by Julie A. Vetalice The 21 companies tracked below collectively grew +3.6% in 1H18 vs. 1H17, still on track to reach our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. Exhibits 1 and 2 reflect 1H18 results for public orthopaedic companies. The performan...
Anika Therapeutics 2Q18 Orthobiologics Revenue +7% YoY
Anika Therapeutics posted 2Q18 orthobiologic revenue of US $26.2MM, +7.0% vs. 2Q17 and 1H18 revenue of
Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers
By Julie A. Vetalice The 21 companies tracked in Exhibits 1 and 2 collectively grew +3.1% in 1Q18 vs. 1Q17, remaining on track alongside our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. (Review
Anika Therapeutics Announces Top-Line Results from CINGAL Trial in Knee OA
In the Phase III 16-02 clinical trial of Anika Therapeutics' CINGAL, statistically significant results in pain reduction
Anika Therapeutics Reports 1Q18 Orthobiologic Revenue
Anika Therapeutics posted 1Q18 orthobiologic revenue of US $19.5MM, -3.6% vs. 1Q17.
Public Orthopaedic Companies: 2017 Revenue and 2018 Sales Drivers
By Julie A. Vetalice The 20 companies tracked in Exhibits 1 and 2 collectively grew +3.0% in 2017 vs. 2016. Individually, you’ll notice some stellar performance in particular segments. (Our final estimates for 2017 orthopaedic industry revenue can be found in
Bioventus Launches Durolane in the US
Bioventus commenced U.S. launch of DUROLANE single-injection hyaluronic acid to treat knee OA pain. 
Anika Therapeutics' 4Q17 and 2017 Orthobiologic Revenue
Anika Therapeutics posted 4Q17 orthobiologic revenue of US $25.1MM, +3.1% vs. 4Q16, and 2017 revenue of
AAOS 2018 First-Time Exhibitors Emphasize Navigation, Orthobiologics, Outcomes
By Julie A. Vetalice In examining the list of AAOS 2018 exhibitors, I see that a number of first-time exhibiting OEMs offer either orthobiologics or navigation…I’m not surprised, as it’s rare for a “new” hip or knee replacement device company to appear, an...
Anika Gains FDA Clearance for HA-based Bone Void Filler
Anika Therapeutics received FDA 510(k) clearance to market a resorbable, injectable hyaluronic acid-based bone void filler...
Majority of Public Orthopaedic Companies Still on Track for Full-Year Guidance
By Julie A. Vetalice Looking at 3Q17 revenue and reading call transcripts, much was said about unforeseen headwinds that crept in before the close of the year, affecting orthopaedic companies in a variety of ways. Following weather events, oft-cited “softness&rdqu...
Anika Therapeutics 3Q17 Revenue +7% vs. 3Q16
Anika Therapeutics posted 3Q17 orthobiologic revenue of US $24.0MM, +7.0% vs. 3Q16, and year-to-date revenue of
Anika Fully Enrolls Second Phase III CINGAL Trial
Anika Therapeutics completed enrollment in its second pivotal Phase III trial evaluating CINGAL® HA/corticoste...
Anika Gains Australia Approval for MONOVISC Viscosupplement
Anika Therapeutics received Australia regulatory approval to market MONOVISC® single-injection viscosupplement for t...
Orthobiologics Activity Signals Collaborations and Clinical Data Essential for Company Growth
By Julie A. Vetalice ORTHOWORLD estimates that global orthobiologic product sales account for ~10% of the orthopaedic market’s revenue, overall. In 2016, that translated to just over $4.9 billion, an increase of 3% vs. 2015. For this year and into 2019, we’re projecting simi...
Sales Results for 20 Orthopaedic Companies: A Mid-year Status Report
By Julie A. Vetalice Now that we’ve collected 1H17 results from 20 publicly-traded companies, I’d like to share some performance-based observations. With now just 4 months remaining in the year, these companies provide a helpful gauge in projecting industry growth.
Study Results: Anika's HYALOFAST in Knee Cartilage Lesions
Studies indicate that Anika Therapeutics' HYALOFAST® scaffold + autologous adult MSCs present a viable option to treat knee ca...
Anika Therapeutics Posts Orthobiologics Sales Growth for 2Q17/1H17
Anika Therapeutics posted 2Q17 orthobiologic revenue of US $24.5MM, +5.0% vs. 2Q16, and 1H17 revenue of
Anika Therapeutics Receives India Regulatory Approval for MONOVISC
Anika Therapeutics received regulatory approval in India for MONOVISC® viscosupplement to treat OA pain...
Anika Therapeutics to Log $5MM Milestone Payment for MONOVISC
Anika Therapeutics will receive a US $5MM milestone payment per terms of the MONOVISC® license agreement
Public and Private Company Revenue Review: 1Q17
By Julie A. Vetalice We're eager to see 2Q17 results to prepare a 1H review for you. In the interim, here are the 1Q17 numbers for publicly-traded companies, with updates and estimates for a number of privately-traded companies, too. Exhibits 1 and 2 illustrate 1Q17 performanc...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2018 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group